IMO, considering the cash burn of a factory, the revenue from that Japanese deal was a pee-hole in the snow. Hardly enough to keep a manufacturing facility from possible bankruptcy. The investors and potential investors need the complete picture in order to place their faith and dough into the deal. That information used to come with some regularity. Hopefully, the new board members will make it their business to keep investors in the loop. Also hopefully, someone will make it their business to get our share of the FDA action that our honorable competitors seem to be garnering.
Market Data 
Markets 
AI
